TNF and ovarian cancer: Nuclear proteins from 2008 ovarian cancer cell line treated with TNF-α were able to shift (bind) oligonucleotide sequences containing the predicted NF-κB binding site of human PIK3CA promoter, but were not able to shift either mutant or mock oligonucleotide sequences (Figure 8 D).